Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
Marlene P Freeman, Rebecca S Hock, George I Papakostas...
https://pubmed.ncbi.nlm.nih.gov/32332464/Actively Recruiting
Led by University of Sao Paulo · Updated on 2026-06-30
468
Participants Needed
1
Research Sites
52 weeks
Total Duration
Suicide is a leading cause of early death worldwide, with rising rates especially in low- and middle-income countries like Brazil where access to specialized care is limited. This trial evaluates whether adding a single esketamine infusion or a Crisis Response Planning session to enhanced treatment as usual eTAU can better prevent future suicide-related events in adolescents and adults aged 14 and older who recently attempted suicide or have severe suicidal thoughts. The study also examines which approach provides faster or longer-lasting improvements in mental health and quality of life, and assesses feasibility and cost-effectiveness in a public health setting. Participants are randomly assigned to one of three groups a single intravenous esketamine infusion with continuous monitoring plus eTAU a 20- to 45-minute Crisis Response Planning session with a trained clinician plus eTAU or eTAU alone, which includes standard emergency care, lethal means safety counseling, connection to mental health services, and a psychiatric follow-up within 7 days. Esketamine is administered in a clinical setting with safety monitoring for up to 24 hours, while Crisis Response Planning involves creating a personalized written and digital safety plan. Participants experiencing a new suicide-related event during the study may receive an open-label combined rescue treatment. Throughout the one-year study, participants complete questionnaires at 11 time points assessing suicidal thoughts, depression, anxiety, sleep, well-being, hopelessness, and quality of life. They provide a blood sample at baseline for exploratory biomarker analysis and use a smartphone app to report mood and thoughts four times daily for four weeks. Safety is monitored continuously, and assessments include a wide range of validated mental health scales. The study reflects real-world emergency care in Brazils public health system and aims to inform scalable suicide prevention strategies.
CONDITIONS
Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities
R
Rodolfo F Damiano, M.D., Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Sao Paulo
Lead Sponsor
Yale University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Immediate intervention with follow-up over 12 months
Participants receive either a single intravenous esketamine infusion with monitoring plus enhanced usual treatment, a Crisis Response Planning session plus enhanced usual treatment, or enhanced usual treatment alone.
11 scheduled assessments over one year
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Marlene P Freeman, Rebecca S Hock, George I Papakostas...
https://pubmed.ncbi.nlm.nih.gov/32332464/Erin F Ward-Ciesielski, Julie A Schumacher, Courtney L Bagge
https://pubmed.ncbi.nlm.nih.gov/27338291/Taylor A Burke, Jessica L Hamilton, Brooke A Ammerman...
https://pubmed.ncbi.nlm.nih.gov/27344029/Sidney Zisook, Isabel Domingues, Jason Compton
https://pubmed.ncbi.nlm.nih.gov/37201142/Ibrahim Turkoz, J Craig Nelson, Samuel T Wilkinson...
https://pubmed.ncbi.nlm.nih.gov/37019044/J E Ware, C D Sherbourne
https://pubmed.ncbi.nlm.nih.gov/1593914/Isobel Marion Harris, Sophie Beese, David Moore
https://pubmed.ncbi.nlm.nih.gov/30947743/C Wang, Y Zhou, W Zheng...
https://pubmed.ncbi.nlm.nih.gov/31483855/Kevork Danayan, Noah Chisamore, Nelson B Rodrigues...
https://pubmed.ncbi.nlm.nih.gov/36889160/Rodolfo Furlan Damiano, Maurício Scopel Hoffmann, Natan Pereira Gosmann...
https://pubmed.ncbi.nlm.nih.gov/36934346/University of Sao Paulo
Lead Sponsor
Yale University
Collaborating Sponsor